Urology Times - BPH news, treatments, and more. - UrologyTimes

ADVERTISEMENT

ADVERTISEMENT

BPH
  • FDA gives nod to combination treatment for BPH


    FDA has approved the 5-alpha-reductase inhibitor dutasteride (Avodart) in combination with the alpha-blocker tamsulosin (Flomax) for treatment of symptomatic enlarged prostate. Both drugs had previously been approved individually for treatment of enlarged prostate.

    Alpha-blocker raises success of trial without catheter


    A trial without catheter (TWOC) following an average of 3 days of catheterization has become standard practice in men with acute urinary retention (AUR) associated with BPH. Now, the results of a recent study have shown that the administration of an alpha-blocker prior to a TWOC can significantly increase the chances of the success of TWOC.

    Therapy combination superior in high-risk BPH patients



    The combination of dutasteride (Avodart) and tamsulosin (Flomax) provides significantly greater improvement in International Prostate Symptom Score (IPSS) and patient-reported quality of life than either therapy alone in men with BPH who are at increased risk of progression.

    Two-drug combination superior in high-risk BPH patients


    The combination of dutasteride (Avodart) and tamsulosin (Flomax) provides significantly greater improvement in International Prostate Symptom Score (IPSS) and patient-reported quality of life than either therapy alone in men with BPH who are at increased risk of progression, according to a 2-year analysis of data from the 4-year Combination of Avodart and Tamsulosin (CombAT) trial.

    Alpha-blocker raises success of trial without catheter


    A trial without catheter (TWOC) following an average of 3 days of catheterization has become standard practice in men with acute urinary retention (AUR) associated with BPH. Now the results of a study presented here have shown that the administration of an alpha-blocker prior to a TWOC can significantly increase the chances of TWOC success.

    TURP, PVP show comparable efficacy in apples-to-apples trial


    Men facing treatment for BPH can expect similar outcomes after transurethral resection of the prostate (TURP) or photoselective vaporization of the prostate (PVP), according to results of a multicenter head-to-head comparison of the two treatments, presented at the AUA annual meeting.

    New in-office BPH laser treatment is efficient, cost-effective


    Biolitec has launched the 150-watt Evolve side-firing diode laser unit, which the company says precisely ablates and coagulates prostate tissue, resulting in shorter procedures and recovery times.

    Use of minimally invasive BPH treatments up significantly


    Use of minimally invasive surgical treatments (MISTs) for BPH has increased tremendously in the past decade, but urologists should be careful about overusing these newer technologies, given the lack of long-term evidence of their efficacy, researchers from the University of Minnesota said here.

    KTP laser shows good results in BPH at 4 years



    Treatment of lower urinary tract symptoms using an 80-watt laser prostatectomy system showed a significant decrease in IPSS and post-void residual urine, among other positive indicators.

Urology Times E-News

Brings you the latest news and information twice each month.

Click here to view the E-News archives.

Sign up now to receive Urology Times E-news free of charge!

ADVERTISEMENT

Urology Times issue
Stay connected to Urology Times
Receive new issue alerts, technology bulletins, and conference updates!

ADVERTISEMENT

EVENTS CALENDAR
Certification Qualifying (Part 1) Exam
August 04 - August 05
AUA Foundation/Society for Basic Urology Research Summer Research Conference on Sexual Medicine
August 07 - August 09
Florida Urological Society Annual Meeting
August 28 - August 31
American Urogynecologic Society Annual Meeting
September 04 - September 06
New York Section of the AUA Annual Meeting
September 07 - September 13
What Do You Think?
Has your use of minimally invasive BPH treatments increased in recent years?
It has increased significantly
It has increased slightly
It has decreased
It has stayed about the same
It has increased significantly
38%
It has increased slightly
31%
It has decreased
0%
It has stayed about the same
31%
View Results
CME SHOWCASE
Management of postoperative ileus
PIN or atypical foci suspicious for PCa on biopsy: Risks and recommendations

Modern Medicine logoUrology Times archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting UrologyTimes.com for fresh content, news, opinions, editor's blogs and more.

Click here